- Home
- SLRX
as 11-24-2025 3:31pm EST
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 3.6M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 5.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -33.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.71 - $108.00 | Next Earning Date: | 11-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Salarius Pharmaceuticals Inc. (SLRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | SLRX | Director | Nov 20 '25 | Buy | $0.75 | 5,000 | $3,740.50 | 5,015 | |
| Rosenblum Mark J | SLRX | Exec VP Finance, CFO | Nov 20 '25 | Buy | $0.80 | 20,000 | $16,000.00 | 20,177 |
Latest Salarius Pharmaceuticals Inc. News
SLRX Breaking Stock News: Dive into SLRX Ticker-Specific Updates for Smart Investing
MT Newswires
6 days ago
Salarius Pharmaceuticals Says S&P Capital IQ Platform Misreported Nasdaq Status After Merger
GlobeNewswire
6 days ago
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
GlobeNewswire
6 days ago
Ewing Sarcoma Market Research Report 2025-2035: Salarius, Eli Lilly, Pfizer, and BioAtla Lead by Driving Innovations in the Development of Novel Targeted Therapies
Associated Press Finance
11 days ago
Salarius: Q3 Earnings Snapshot
MT Newswires
12 days ago
Salarius Pharmaceuticals Completes Merger With Decoy Therapeutics
GlobeNewswire
12 days ago
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Associated Press Finance
13 days ago
BC-Most Active Stocks
MT Newswires
14 days ago
Top Midday Decliners
Compare SLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLRX Salarius Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.